WOBURN, Mass.--(BUSINESS WIRE)--ArQule, Inc. (NASDAQ: ARQL) today announced that the Company is presenting several pre-clinical and early clinical-stage studies at the American Association for Cancer Research (AACR) 101st Annual Meeting, April 17-21, 2010 in Washington, D.C. that relate to the ongoing development of: ARQ 621, a novel inhibitor of the Eg5 kinesin motor protein in Phase 1 clinical testing; ARQ 736, a novel inhibitor of BRAF in pre-clinical development; and ARQ 501, an activator of the DNA damage response mechanism mediated by the E2F-1 transcription factor that has completed initial clinical testing.
